knowledge -WSS

knowledge

author：focus 2025-10-01 00:30:36 - browse：5

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Researchers CRISPR chickens in bid to protect them from bird flu

leisure time

WSS

A revolution in caring for preterm infants

Bristol 'take

Medicare to cover more brain scans related to Alzheimer’s drugs

Stroke deaths set to near 10 million globally by 2050

A Q&A with the global head of Boehringer Ingelheim's innovation unit

When women are denied an abortion, their children fare worse than peers

hotspot

knowledge

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Physician executives need more than on

Walensky prepares to leave CDC — and Congress — behind

When women are denied an abortion, their children fare worse than peers

Wildfire smoke exposes gaps in outdoor worker protections

When women are denied an abortion, their children fare worse than peers

Anesthesiologist group: stop taking Ozempic before surgery

Humana CEO Bruce Broussard to step down in 2024

How to save PrEP access — and even expand it

STAT Readout Newsletter: Today in biotech, life science news

focus

Humana CEO Bruce Broussard to step down in 2024

How clinical AI models' predictive power can degrade over time

The future of health care in the House

What the Wegovy shortage looks like for doctors — and for patients

Better Therapeutics data on benefit with GLP

Better Therapeutics data on benefit with GLP

focus

leisure time

leisure time

Wikipedia